Global DNA Damage Response Targeting Therapeutics Markets, 2021-2030 by Target Disease Indication, Therapeutic Area, Target Molecule, Type of…

DUBLIN--(BUSINESS WIRE)--The "DNA Damage Response Targeting Therapeutics Market by Target Disease Indication, Therapeutic Area, Target Molecule, Type of Molecule, Route of Administration, and by Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

The DNA Damage Response Targeting Therapeutics (beyond PARP inhibitors) Market report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of DNA damage response targeting therapeutics in the healthcare industry, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.

Currently, there are four approved poly-ADP ribose polymerase (PARP) inhibitor drugs that are based on the inhibition of the DNA damage repair process in advanced stage oncological indications. Further, drug developers across the world, claim to be evaluating several other molecular targets, such as ATM, ATR, CHK1, and WEE1, within the DNA damage response pathway.

Although majority of the drug candidates for molecular targets (other than PARP) are in the preclinical / initial clinical stages, drug developers are optimistic regarding the therapeutic potential of this emerging class of drugs. Gradually, a substantial body of evidence, validating the efficacy of drugging the aforementioned biological targets, is being generated through extensive research in this field; this is reflected in the rapidly growing number of research publications and patents focused on this subject.

Driven by encouraging clinical trial results, this niche, but upcoming market, is poised to witness healthy growth over the next decade, with pioneers in the field likely to benefit from the first-to-market advantage.

One of the key objectives of the report was to estimate the existing market size and future opportunity for DNA damage response targeting therapeutics developers, over the next decade. Further, we have provided an informed estimate of the evolution of the market, during the period 2021-2030, based on several relevant parameters, such as adoption trends, and expected price variations for these products.

Additionally, the report features the likely distribution of the current and forecasted opportunity within DNA damage response targeting therapeutics market across

Key Questions Answered

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape

5. Key Insights

6. Company Profiles

7. Clinical Trials Analysis

8. Publication Analysis

9. Analysis Of Key Parameters Impacting Drug Pricing And Adoption

10. Market Forecast

11. Concluding Remarks

12. Appendix I: Tabulated Data

13. Appendix Ii: List Of Companies And Organization

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/2pv1u0

Read the original:
Global DNA Damage Response Targeting Therapeutics Markets, 2021-2030 by Target Disease Indication, Therapeutic Area, Target Molecule, Type of...